S. Gail Eckhardt - Concepedia

Author

S. Gail Eckhardt

Also Known As

Miller, C. Ryan, S ECKHARDT, S Eckhardt, S G Eckhardt, S Gail Eckhardt, S Kerpel-Fronius, S. Eckhardt, S. G. Eckhardt, S. Gail Eckhardt, S. Gail Eckhardt (387179)

280

Publications

7.3K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Denver University of Colorado Anschutz Medical Campus University of Colorado Cancer Center The University of Texas at Austin Livestrong Foundation

About

S. Gail Eckhardt is an author at University of Colorado Denver specializing in medicine, cancer research, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	21	1.4K
2	Cell Biology	10	11	499
3	Health Sciences	2	2	54
4	Natural Sciences	2	2	372
5	Biochemistry	2	2	199

S. Gail Eckhardt

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer Ghassan K. Abou‐Alfa, Richard Létourneau, Graydon Harker, Journal of Clinical Oncology	2006	277
Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152) John A. Flygare, Maureen H. Beresini, Nageshwar Budha, Journal of Medicinal Chemistry ApoptosisCell DeathClinical CandidatePharmacotherapyImmunotherapeutics	2012	247
Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer Christopher H. Lieu, Erica A. Golemis, Ilya G. Serebriiskii, Clinical Cancer Research	2019	236
Phase I Study of Recombinant Human CD40 Ligand in Cancer Patients Robert H. Vonderheide, Janice P. Dutcher, Jeanne E. Anderson, Journal of Clinical Oncology	2001	224
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation David Rinaldi, John G. Kuhn, Howard A. Burris, Cancer Chemotherapy and Pharmacology Medicinal ChemistryPharmaceutical SciencePreclinical Drug EvaluationContinual Reassessment MethodDose Escalation	1999	174
Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer John Nemunaitis, Jon Holmlund, Maura A. Kraynak, Journal of Clinical Oncology	1999	172
A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas Lia Gore, Mace L. Rothenberg, Cindy L. O’Bryant, Clinical Cancer Research	2008	167
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts Anna Capasso, Julie Lang, Todd M. Pitts, Journal for ImmunoTherapy of Cancer	2019	166
Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors Michael S. Gordon, Christopher J. Sweeney, David S. Mendelson, Clinical Cancer Research	2010	159
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. Eric K. Rowinsky, Lee Smith, Y M Wang, Journal of Clinical Oncology	1998	146

Page 1